S1 E4. Kidney transplant equity discussions are translating into action. But can the transplant workup widen disparities? With Dr. Velma Scantlebury.
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
S1 E4. Kidney transplant equity discussions are translating into action. But can the transplant workup widen disparities? With Dr. Velma Scantlebury.
-
ナレーター：
-
著者：
このコンテンツについて
In this episode of Kidney Transplant Conversations, we are joined by history maker Dr. Velma Scantlebury, who became the first Black female transplant surgeon in the US in 1989.
In a wide-ranging discussion we ask whether all the current talk about health equity is resulting in real action, and we explore several current examples of intentional change. Firstly, the “Boldly Against Racism” Campaign at the American Society of Transplant Surgeons (ASTS); secondly, the updated Hippocratic Oath at Columbia University Vagelos College of Physicians and Surgeons, clearly centering health equity, diversity, and inclusion; and thirdly the recent recommendations affecting the way that kidney function calculations (eGFR) are made. Dr. Scantlebury also shares her concerns that patients with fewer resources are being disadvantaged by the burden of appointments required in preparing for a transplant and this may extend how long patients are kept on dialysis, acting as a potential barrier to transplantation.
We also discuss ways that consideration of social determinants, along with a more diverse healthcare team, can help improve the quality of care for kidney disease patients, and help to increase the number of kidney transplants received. With podcast host Rolf Taylor.
All views and opinions expressed in this podcast reflect those of the participants.
We thank the participants and advisors who help make Kidney Transplant Conversations possible.
Kidney Transplant Conversations is underwritten by Veloxis Pharmaceuticals, Inc. All views and opinions expressed in the podcast reflect those of the participants and do not necessarily represent the views and opinions of Veloxis Pharmaceuticals, Inc.
© Project Advocacy, 2022-2023